Cargando…

Teprotumumab for the treatment of chronic thyroid eye disease

BACKGROUND: Teprotumumab, a novel IGF-1R antibody was recently shown to significantly reduce the signs of active Thyroid eye disease (TED). The current study reviews its efficacy in chronic TED. METHODS: In this retrospective review, consecutive patients with chronic stable TED (>2 years), who ha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ugradar, Shoaib, Kang, Julia, Kossler, Andrea L., Zimmerman, Erin, Braun, Jenna, Harrison, Andrew R., Bose, Swaraj, Cockerham, Kimberly, Douglas, Raymond S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307784/ https://www.ncbi.nlm.nih.gov/pubmed/34244669 http://dx.doi.org/10.1038/s41433-021-01593-z

Ejemplares similares

Facial and Eyelid Changes in Thyroid Eye Disease Are Reversed by Teprotumumab
por: Ugradar, Shoaib, et al.
Publicado: (2021)

Thyroid dermopathy responds to teprotumumab therapy
por: Crespo-Trevino, Ricaurte, et al.
Publicado: (2022)

Improvement of asymmetric thyroid eye disease with teprotumumab
por: Ugradar, Shoaib, et al.
Publicado: (2022)

Teprotumumab for thyroid eye disease: early response is not required for benefit
por: Ugradar, Shoaib, et al.
Publicado: (2021)

Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease
por: Kossler, Andrea Lora, et al.
Publicado: (2022)

Expert Consensus on the Use of Teprotumumab for the Management of Thyroid Eye Disease Using a Modified-Delphi Approach
por: Douglas, Raymond S., et al.
Publicado: (2022)

LBSAT238 Teprotumumab Reduces Orbital Fat And Muscle Volume In Patients With Thyroid Eye Disease
por: Ugradar, Shoaib
Publicado: (2022)

Early efficacy of teprotumumab for the treatment of dysthyroid optic neuropathy: A multicenter study
por: Sears, Connie M., et al.
Publicado: (2021)

RF35 | PSAT268 Reversal of Graves’ Disease Associated Facial Volume Expansion and Eyelid Changes Following Teprotumumab Therapy
por: Ugradar, Shoaib, et al.
Publicado: (2022)

Hearing Loss and Teprotumumab
por: Kossler, Andrea, et al.
Publicado: (2021)

Proptosis and Diplopia Response With Teprotumumab and Placebo vs the Recommended Treatment Regimen With Intravenous Methylprednisolone in Moderate to Severe Thyroid Eye Disease: A Meta-analysis and Matching-Adjusted Indirect Comparison
por: Douglas, Raymond S., et al.
Publicado: (2022)

Early experience with teprotumumab for chronic thyroid eye disease
por: Ozzello, Daniel J., et al.
Publicado: (2020)

Changing the face of thyroid eye disease
por: Ugradar, Shoaib, et al.
Publicado: (2022)

Efficacy and Safety of Teprotumumab in Thyroid Eye Disease
por: Teo, Honeylen Maryl, et al.
Publicado: (2021)

Teprotumumab in advanced reactivated thyroid eye disease
por: Cheng, Olivia T., et al.
Publicado: (2022)

Teprotumumab: A Review in Thyroid Eye Disease
por: Nie, Tina, et al.
Publicado: (2022)

The Effect of Teprotumumab on Eyelid Position in Patients with Thyroid Eye Disease
por: Simmons, Brittany A., et al.
Publicado: (2022)

Correction: Teprotumumab: A Review in Thyroid Eye Disease
por: Nie, Tina, et al.
Publicado: (2022)

Teprotumumab in thyroid eye disease: wonder drug or great divider?
por: Perros, Petros, et al.
Publicado: (2023)

FRI572 Teprotumumab In Unexplored Presentation Of Thyroid Eye Disease
por: Torres Torres, Marina T, et al.
Publicado: (2023)

Effects of teprotumumab on patients with long-standing, active thyroid eye disease
por: Vinson, Kyle B., et al.
Publicado: (2022)

Rapidly progressive cognitive decline associated with teprotumumab in thyroid eye disease
por: Hoang, Thanh Duc, et al.
Publicado: (2021)

Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis
por: Douglas, Raymond S.
Publicado: (2018)

A case of ulcerative colitis associated with teprotumumab treatment for thyroid eye disease
por: Safo, Myra B., et al.
Publicado: (2021)

Oral Corticosteroids for Teprotumumab-Related Hearing Loss: A Case Report
por: Lu, Tracy J., et al.
Publicado: (2023)

FRI545 Durability Of Treatment Response With VRDN-001, A Full Antagonist Antibody To IGF-1 Receptor, In Patients With Thyroid Eye Disease (TED): Phase 1/2 Clinical Study
por: Douglas, Raymond, et al.
Publicado: (2023)

Intraocular pressure improvement in patients receiving teprotumumab for the treatment of thyroid eye disease: a case series
por: Chu, Matthew, et al.
Publicado: (2022)

Retinal Surface Macrophage Changes in Thyroid Eye Disease before and after Treatment with Teprotumumab
por: Otero-Marquez, Oscar, et al.
Publicado: (2022)

Audiologic Demonstration of Ototoxicity From Teprotumumab Treatment in a Patient With Thyroid Eye Disease
por: Najjar, Wassim, et al.
Publicado: (2022)

Elasomeran/teprotumumab: Thyroid-eye disease flare, diarrhoea and muscle spasms: case report
Publicado: (2022)

RF35 | PSAT263 Efficacy of Teprotumumab for Thyroid Eye Disease in Hypothyroid Patients
por: Smith, Terry J, et al.
Publicado: (2022)

PSAT261 Use of Steroids Pre- and Post-Teprotumumab in Thyroid Eye Disease Patients
por: Holt, Robert J, et al.
Publicado: (2022)

The Efficacy and Safety of Teprotumumab in Thyroid Eye Disease: Evidence from Randomized Controlled Trials
por: Lin, Fei, et al.
Publicado: (2023)

Graves' disease complicated by concurrent thyroid eye disease and pretibial myxedema successfully treated with teprotumumab
por: Bowens, Brendan K., et al.
Publicado: (2022)

Effects of Smoking on Outcomes of Thyroid Eye Disease Treated with Teprotumumab: A Retrospective Cohort Study
por: O’Dell, Jordan Miller, et al.
Publicado: (2023)

Teprotumumab-trbw as a Novel Monoclonal Antibody for Thyroid Eye Disease: A Literature Review
por: Bocklud, Brooke E, et al.
Publicado: (2023)

Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy
por: Smith, Terry J.
Publicado: (2020)

Effect of teprotumumab on intraocular pressure in thyroid-associated ophthalmopathy
por: Adetunji, Modupe O., et al.
Publicado: (2022)

OR27-04 Efficacy And Safety Results From The Randomized, Placebo-controlled Multicenter Trial With Teprotumumab In Chronic-Low Clinical Activity Score Thyroid Eye Disease Patients
por: Douglas, Raymond S, et al.
Publicado: (2023)

Teprotumumab for the treatment of mild compressive optic neuropathy in thyroid eye disease: A report of two cases
por: Chiou, Carolina A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qph23imfi8dgv5k1h879g4bh5j